Lyell Immunopharma Inc
NASDAQ:LYEL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.8583
3.07
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LYEL stock under the Base Case scenario is 0.72 USD. Compared to the current market price of 0.97 USD, Lyell Immunopharma Inc is Overvalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Lyell Immunopharma Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LYEL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Lyell Immunopharma Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Lyell Immunopharma Inc
Balance Sheet Decomposition
Lyell Immunopharma Inc
Current Assets | 450m |
Cash & Short-Term Investments | 440.5m |
Other Current Assets | 9.5m |
Non-Current Assets | 169.2m |
Long-Term Investments | 39.1m |
PP&E | 124.7m |
Other Non-Current Assets | 5.3m |
Current Liabilities | 33.5m |
Accounts Payable | 3.6m |
Accrued Liabilities | 29m |
Other Current Liabilities | 907k |
Non-Current Liabilities | 55m |
Other Non-Current Liabilities | 55m |
Earnings Waterfall
Lyell Immunopharma Inc
Revenue
|
63k
USD
|
Operating Expenses
|
-217.2m
USD
|
Operating Income
|
-217.1m
USD
|
Other Expenses
|
13.1m
USD
|
Net Income
|
-204m
USD
|
Free Cash Flow Analysis
Lyell Immunopharma Inc
USD | |
Free Cash Flow | USD |
LYEL Profitability Score
Profitability Due Diligence
Lyell Immunopharma Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
Score
Lyell Immunopharma Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
LYEL Solvency Score
Solvency Due Diligence
Lyell Immunopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Lyell Immunopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LYEL Price Targets Summary
Lyell Immunopharma Inc
According to Wall Street analysts, the average 1-year price target for LYEL is 2.04 USD with a low forecast of 1.01 USD and a high forecast of 4.2 USD.
Dividends
Current shareholder yield for LYEL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
LYEL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 219 full-time employees. The company went IPO on 2021-06-17. The firm offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. The company builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). The company offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. The company utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.
Contact
IPO
Employees
Officers
The intrinsic value of one LYEL stock under the Base Case scenario is 0.72 USD.
Compared to the current market price of 0.97 USD, Lyell Immunopharma Inc is Overvalued by 25%.